Core Insights - Hemostemix Inc. has received conditional approval from the TSX Venture Exchange for a non-brokered private placement amounting to CDN $280,594, involving the issuance of 2,244,752 Common Shares at a price of CDN $0.125 per share [1][2] Company Overview - Hemostemix is a leading autologous stem cell therapy company, founded in 2003, specializing in VesCell™ (ACP-01) for various cardiovascular conditions [4] - The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications [4] - ACP-01 has shown significant clinical relevance and safety as a treatment for conditions such as peripheral arterial disease and chronic limb threatening ischemia, with a reported 0% mortality rate in a specific patient population over 4.5 years [4] Use of Proceeds - The proceeds from the private placement will be allocated to general working capital purposes, supporting ongoing operational expenses and business development activities [2] Regulatory Compliance - All securities issued in connection with the offering are subject to a four-month hold period under Canadian securities laws [3]

Core Viewpoint - RCI Hospitality Holdings, Inc. is facing a securities class action lawsuit due to allegations of tax fraud and bribery, with a lead plaintiff deadline set for November 20, 2025 [1][5]. Group 1: Class Action Details - The class action pertains to securities purchased between December 15, 2021, and September 16, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [2][5]. - The lawsuit claims that the defendants made materially false statements and failed to disclose significant legal risks, leading to investor damages when the truth emerged [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Primo Brands To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities: (a) the common stock of Primo Water between June 17, 2024 through November 8, 2024, inclusive, and/or (b) the common stock of Primo Brands between November 11, 2024 through November 6, 2025, inclusive (collectively, the "Class Period") and would like to discuss your legal rights, call Faruqi & ...

Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Canadian Critical Minerals Corp. (TSXV: CCMI) (OTCQB: RIINF) ("CCMI" or the "Company") is pleased to announce a private placement of a minimum of 10,000,000 units of the Company (each, a "Unit") and a maximum of 28,571,428 Units at a price of $0.035 per Unit for aggregate gross proceeds of a minimum of $350,000 and a maximum of $1,000,000 (the "Offering"). Each Unit is comprised of one common share of the Company (a "Common Share") and one common sha ...

Core Points - RIWI Corp. has granted 50,000 stock options to key employees, exercisable at CAD $0.51 per share, expiring on November 18, 2030 [1] Company Overview - RIWI is a market research platform and global trend-tracking and prediction technology firm, offering tracking surveys, continuous risk monitoring, predictive analytics, and ad effectiveness tests on a subscription basis [2]

Core Insights - Ardent Health, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company reported a $43 million reduction in revenue and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2] - Following the announcement, Ardent's stock experienced a significant decline during pre-market trading [3] Financial Performance - Ardent Health disclosed a $43 million decrease in revenue due to changes in accounting estimates related to accounts receivable [2] - The company also reported a $54 million increase in professional liability reserves for claims in New Mexico [2] Market Reaction - The announcement of the financial results led to a notable drop in Ardent's common stock during pre-market trading on November 13, 2025 [3]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4].

Core Points - StrikePoint Gold Inc. has successfully closed its non-brokered private placement under the Listed Issuer Financing Exemption, raising gross proceeds of CAD $3.1 million [1][5] - The offering consisted of 20,797,460 units priced at CAD $0.15 each, with each unit comprising one common share and one warrant [1][2] - The warrants allow holders to purchase additional common shares at CAD $0.30 until November 18, 2027 [2] Financial Details - The total gross proceeds from the offering amounted to CAD $3,119,619 [1] - Finder's fees paid in connection with the offering totaled CAD $161,416.50, along with the issuance of 1,076,110 non-transferable warrants [4] - Insiders subscribed for 199,460 units, contributing CAD $29,919 to the gross proceeds [6] Use of Proceeds - The net proceeds from the LIFE Offering will be allocated towards exploration activities at the Hercules Gold Project and the Cuprite Gold Project in Nevada, as well as for general working capital [5] Regulatory Compliance - The offering was conducted under the Listed Issuer Financing Exemption, which allows for the securities to be sold without a hold period, except for the warrants which have a 60-day exercise restriction [3] - The issuance to insiders is classified as a related party transaction, with the company relying on exemptions from formal valuation and minority shareholder approval requirements [6] Company Overview - StrikePoint Gold Inc. is focused on gold exploration in the Western United States and Canada, with approximately 145 square kilometers of mineral claims [8][10] - The management team, led by CEO Michael G. Allen, has extensive experience in exploration and finance, having completed multiple transactions in the mining sector [11]

Core Viewpoint - A class action securities lawsuit has been filed against Synopsys, Inc. to recover losses incurred by shareholders due to alleged securities fraud between December 4, 2024, and September 9, 2025 [2]. Group 1: Lawsuit Details - The lawsuit alleges that Synopsys, Inc. made false statements and concealed information regarding the negative impact of its increased focus on artificial intelligence customers on the economics of its Design IP business [3]. - It is claimed that certain decisions regarding the company's roadmap and resources were unlikely to achieve their intended results, which materially affected financial outcomes [3]. - The lawsuit asserts that the positive statements made by the defendants about the company's business and prospects were misleading and lacked a reasonable basis [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses in Synopsys, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders, having ranked in the Top 50 Report for seven consecutive years [5].

Core Insights - Cingulate Inc. is making significant progress in transforming CTx-1301 into a commercial ADHD franchise, with key milestones achieved [1][5] - The FDA has accepted the NDA for CTx-1301, with a PDUFA date set for May 31, 2026, indicating a potential launch in 2026 pending approval [5] - The company has secured a commercial supply agreement with Bend Bio Sciences to ensure U.S. manufacturing capacity ahead of the product launch [1][5] Financial Position - As of the end of the quarter, Cingulate reported approximately $6.1 million in cash [5] - A $6 million financing post-quarter has extended the company's runway into the second quarter of 2026 [5] Commercial Strategy - The commercial build is advancing with the appointment of Bryan Downey as Chief Commercial Officer [5] - Partnerships with Indegene and Bend Bio Sciences are part of the strategy to secure manufacturing and commercial capabilities [5]